Señales en vivo de KAN.ST | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 11:29):

Stats
Volumen de hoy	932 989
Volumen promedio	390 190
Capitalización de mercado	175.81M
EPS	SEK0 ( 2024-02-22 )
Próxima fecha de ganancias	( SEK-0.200 ) 2024-05-17
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-2.00
ATR14	SEK0.00800 (0.53%)

Volumen Correlación

Largo: 0.05 (neutral)

Corto: -0.72 (moderate negative)

Signal:(59.836) Neutral

Kancera AB (publ) Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Kancera AB (publ) Correlación - Moneda/Commodity

0.00
( neutral )

0.18
( neutral )

0.00
( neutral )

-0.04
( neutral )

-0.29
( neutral )

-0.10
( neutral )

Kancera AB (publ) Finanzas

Annual	2023
Ingresos:	SEK0
Beneficio Bruto:	SEK-3.00M (0.00 %)
EPS:	SEK-0.800

FY	2023
Ingresos:	SEK0
Beneficio Bruto:	SEK-3.00M (0.00 %)
EPS:	SEK-0.800

FY	2022
Ingresos:	SEK753 000
Beneficio Bruto:	SEK393 000 (52.19 %)
EPS:	SEK-0.880

Financial Reports:

No articles found.

Kancera AB (publ)

Kancera AB (Publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. It also develops HDAC for the treatment of nerve inflammation and pain; and ROR1 inhibitors for the treatment of solid tumors and blood cancers. Kancera AB (Publ) was founded in 2010 and is based in Solna, Sweden.